Group 1 - The core viewpoint of the article is that CITIC Securities has conducted a thorough review of Shennong Industry Co., Ltd.'s temporary use of idle raised funds to supplement working capital, ensuring compliance with relevant regulations and that it will not affect the company's investment plans [1][6] Group 2 - The company raised a total of 3 billion yuan by issuing 30 million convertible bonds at a face value of 100 yuan each, as approved by the China Securities Regulatory Commission [1][2] - The company has established a special account for the management and use of the raised funds, in accordance with regulatory requirements [2] - The company previously approved the temporary use of up to 1 billion yuan of idle raised funds to supplement working capital, with a repayment deadline of 12 months from the board's approval date [2][3] Group 3 - The company has cumulatively used 1.81892 billion yuan of the raised funds for various projects, with a total investment amount of 5.98567 billion yuan [4][5] - The company plans to use up to 800 million yuan of idle raised funds temporarily to supplement working capital, ensuring that it does not impact the progress of investment projects [5][6] Group 4 - The board and supervisory committee of the company have approved the use of idle raised funds, confirming that the decision-making process complies with relevant regulations [6] - The supervisory committee believes that the temporary use of idle funds will enhance the efficiency of fund utilization and reduce financial costs without harming shareholder interests [6]

Core Viewpoint - The company intends to change part of the raised funds to permanently supplement its working capital, which is deemed a reasonable decision based on current industry conditions and business development needs [3][6]. Fundraising Basic Situation - In July 2017, the company raised a net amount of approximately 590.16 million yuan from a non-public offering of 45,511,698 shares, after deducting issuance costs [1]. - The funds were verified by an accounting firm and a report was issued confirming the amount [1]. Fund Usage Status - As of June 30, 2025, the total balance of the raised funds is approximately 363.39 million yuan, with specific balances in various bank accounts and financial products [2]. - The company has utilized approximately 282.36 million yuan of the raised funds for investment projects [2]. Reasons for Permanent Supplementation of Working Capital - The company has not identified suitable investment projects for part of the raised funds, totaling approximately 110.72 million yuan, and aims to enhance cash flow and operational capacity by reallocating these funds [3][4]. Impact of Fund Reallocation - The decision to permanently supplement working capital is expected to improve fund utilization efficiency and will not adversely affect the company's normal operations or existing investment projects [3][6]. Related Review Procedures - The board of directors and the supervisory board have approved the proposal to reallocate the funds, which will be submitted for shareholder approval [4][6].

Core Viewpoint - The company is utilizing part of the idle funds raised from a non-public offering to temporarily supplement its working capital, which is deemed necessary for operational efficiency and financial management [1][5][6]. Summary by Sections 1. Non-Public Offering Fund Details - In 2017, the company raised a total of RMB 1,306,108,798.84 through a non-public offering of 74,720,183 shares at RMB 17.48 per share, with net proceeds amounting to RMB 1,288,808,798.84 after deducting issuance costs [1]. - As of June 30, 2025, the company has utilized RMB 910,351,700 for various projects, including RMB 224,940,400 for self-funded projects [2][3]. 2. Fund Utilization and Remaining Balance - The company has invested in several projects, with the following actual investment amounts: - Chemical Preparation International Industrialization Project: RMB 545,134,000 - Lianhua Qingwen Capsule International Registration Project: RMB 206,108,800 - Lianhua Qingwen Series Product Capacity Enhancement Project: RMB 254,866,000 - Supplementing Working Capital: RMB 300,000,000 - Total: RMB 1,306,108,800 [3][4]. - As of June 30, 2025, the remaining balance of the non-public offering funds is RMB 50,706,684.42 [4][5]. 3. Temporary Working Capital Supplement - The company plans to use up to RMB 150,000,000 of idle funds to temporarily supplement working capital, with a usage period not exceeding 12 months [5][6]. - The decision is based on the expectation that approximately RMB 150,000,000 will be idle in the Chemical Preparation International Industrialization Project over the next 12 months, aiming to enhance fund utilization efficiency and reduce financial costs [5][6]. 4. Approval and Compliance - The proposal to use idle funds for working capital has been approved by the company's board and is compliant with relevant regulations, ensuring that it does not affect the ongoing projects or shareholder interests [6][7].

Summary of Key Points Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the implementation of its fundraising investment projects [1][4][6]. Group 1: Fundraising Overview - The company raised a total of RMB 894,999,954.16, with a net amount of RMB 875,792,998.29 after deducting related expenses [1][2]. - The funds were raised through the issuance of 96,030,038 shares at a price of RMB 9.32 per share, approved by the China Securities Regulatory Commission on June 26, 2023 [1]. Group 2: Fund Management and Usage - The company has established a fundraising supervision account and signed a tripartite/four-party supervision agreement with the sponsor and relevant banks [2]. - As of July 1, 2025, the company has used RMB 69,363.46 million of the raised funds, leaving RMB 18,985.96 million (including interest and net cash management income) unutilized [2]. Group 3: Temporary Fund Usage - The company plans to use up to RMB 17,500 million of idle funds to temporarily supplement working capital, with a usage period of up to 12 months from the board's approval [4][5]. - This temporary use of funds is expected to save approximately RMB 5.25 million in financial costs based on the current one-year loan market quotation rate of 3% [4]. Group 4: Compliance and Approval - The board and supervisory committee have approved the use of idle funds, confirming that it will not affect the normal progress of fundraising investment projects [6]. - The sponsor has verified that the company's actions comply with relevant regulations and do not change the intended use of the raised funds [6].

Core Viewpoint - The company intends to temporarily use part of its idle raised funds to supplement working capital, ensuring that this does not affect the normal progress of its fundraising investment projects [6][9]. Group 1: Fundraising Overview - The company was approved to publicly issue 70.6 million shares at a price of RMB 13.39 per share, raising a total of RMB 945.334 million, with a net amount of RMB 843.209 million after deducting issuance costs [2][3]. - As of the date of the verification opinion, the remaining balance of the raised funds is RMB 192.519 million, including oversubscription funds [6]. Group 2: Fund Utilization - The company has used RMB 496.663 million of the raised funds for third-party medical device logistics construction projects [4]. - The company plans to use up to RMB 92.75 million of idle raised funds temporarily to supplement working capital, with a usage period not exceeding 12 months [7][9]. Group 3: Approval and Oversight - The board of directors and the supervisory board have approved the use of idle funds, ensuring compliance with relevant regulations [9][10]. - The company will open a special account at a bank for the management of these funds and sign a tripartite supervision agreement to oversee the storage and usage of the raised funds [8]. Group 4: Financial Efficiency - By utilizing the idle funds, the company expects to save approximately RMB 2.78 million in financial costs based on the current loan market rate of 3.00% [8].

Summary of Key Points Core Viewpoint - The company intends to use part of the temporarily idle raised funds to supplement its working capital, which is deemed necessary for improving fund utilization efficiency and reducing financial costs [2][6][9]. Group 1: Fundraising Overview - The company issued 13,794,971 convertible bonds at a face value of 100 RMB each, raising a total of 1,379,497,100 RMB, with a net amount of 1,357,031,302.96 RMB after deducting underwriting fees [2][3]. - The funds are stored in a dedicated account as per the regulatory requirements, and a tripartite supervision agreement has been signed [3][4]. Group 2: Fund Utilization Plan - Originally, the raised funds were planned for specific projects, including the development of natural gas resources in the Shilou West Block, with a total investment of 137,949.71 million RMB [3][4]. - The company has proposed to use up to 40,000 million RMB of temporarily idle funds to supplement working capital, with a usage period not exceeding 12 months [5][6]. Group 3: Financial Efficiency - The company operates in a capital-intensive industry, necessitating the use of various financing sources, including loans, to support its operations [6][7]. - By utilizing idle funds for working capital, the company expects to save approximately 3.00% in financial costs based on current loan market rates [6][7]. Group 4: Internal Decision-Making Process - The board of directors and the supervisory board have approved the use of idle funds, confirming that the necessary internal procedures were followed [7][9]. - The funds can be used in a rolling manner within the approved limits and timeframe, ensuring that they will be returned to the dedicated account as needed [7][9].

特此公告 浙江省建设投资集团股份有限公司 董事会 二零二五年六月十六日 在授权额度和期限内，公司实际使用暂时闲置的募集资金共计人民币 30,000 万元暂时用 于补充流动资金。公司对这部分募集资金进行了合理安排与使用，未影响募集资金投资项目的 正常进行。截至 2025 年 6 月 16 日，公司已将上述暂时补充流动资金的募集资金共计人民币 集资金的归还情况通知了公司的保荐机构及保荐代表人。 证券代码：002761 证券简称：浙江建投 公告编号：2025-063 债券代码：127102 债券简称：浙建转债 浙江省建设投资集团股份有限公司 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 浙江省建设投资集团股份有限公司（以下简称"公司"）于 2024 年 6 月 17 日召开了第 四届董事会第三十九次会议及第四届监事会第二十六次会议，审议通过了《关于使用部分闲置 募集资金暂时补充流动资金的议案》，同意公司在保证募集资金投资项目建设的资金需求、保 证募集资金投资项目正常进行的前提下，拟使用发行可转债募集的总额不超过 30,000 万元人 民币的闲置募集资金暂时用于补充 ...

Group 1 - The sixth session of the Supervisory Board of Nanjing Baose Co., Ltd. held its tenth meeting on June 13, 2025, via communication methods, with all five supervisors present [1][2]. - The Supervisory Board approved the temporary use of up to 200 million yuan of idle raised funds to supplement working capital, which is expected to meet the company's daily operational funding needs and reduce financial expenses [1][2]. - The decision to use part of the idle raised funds does not conflict with the implementation plan of the investment projects funded by the raised capital and is in the interest of the company and all shareholders [1][2]. Group 2 - The voting results of the meeting were unanimous, with 5 votes in favor, 0 against, and 0 abstentions [2]. - The announcement regarding the use of idle raised funds was also published on the designated information disclosure website of the China Securities Regulatory Commission [2]. - The meeting and its resolutions complied with relevant regulations, ensuring legality and effectiveness [1].

Core Viewpoint - The company, Sely Medical, is undergoing significant changes in its funding strategy, including the termination of a specific investment project and the reallocation of remaining funds to enhance liquidity [1][2][3]. Group 1: Company Financials - As of June 6, 2025, Sely Medical's stock closed at 12.18 yuan, down 2.87% from the previous week [1]. - The company's total market capitalization is 2.327 billion yuan, ranking 30th in the pharmaceutical commercial sector and 4723rd in the A-share market [1]. Group 2: Fundraising and Project Updates - The company has fully repaid all funds raised for temporary liquidity support from its 2018 non-public A-share issuance [3]. - Sely Medical plans to terminate the "Expansion of Medical Testing Centralized Marketing and Service Business Scale Project" from its 2018 fundraising, reallocating the remaining 17253.61 million yuan to permanent liquidity support [2][3]. - The decision to terminate the project is attributed to changes in IVD industry policies, market environment shifts, and necessary strategic adjustments by the company [2]. Group 3: Upcoming Events - Sely Medical will hold its third extraordinary general meeting of shareholders on June 20, 2025, to review the proposal regarding the termination of the investment project and the reallocation of funds [2][3].

Core Points - The company held its 2025 second meeting of the 11th Board of Directors on June 6, 2025, via communication voting [1] - The board approved the addition of members to certain specialized committees [1] - The board also approved the temporary use of idle raised funds amounting to 213.5 million yuan to supplement the company's working capital [1][2] Group 1 - The board meeting was conducted in accordance with relevant laws and regulations, ensuring the legality and validity of the resolutions [1] - The resolution for the addition of committee members received unanimous support with 7 votes in favor [1] - The resolution to use idle funds aims to enhance the efficiency of fund utilization and reduce operational costs while ensuring the needs of investment projects are met [1] Group 2 - The temporary use of 213.5 million yuan is intended to support the company's and its subsidiaries' working capital needs for a period not exceeding 12 months [1] - The decision reflects the company's commitment to maximizing shareholder interests [1]